Nov. 18, 2020

BioVersys Announces First Subjects Dosed in Phase 1 Clinical Trial of BV100

Today marks the start of the World Antimicrobial Awareness Week 2020 by the WHO, underlining once more the incredibly important health emergency that antimicrobial resistance is causing on global healthcare systems. On this day, BioVersys is extremely proud to announce the successful start of its first clinical trial for our Lead product BV100. BV100 is developed to address the WHO and CDC top priority infection of Carbapenem Resistant Acinetobacter baumannii in critically ill patients. Please refer to our PR for additional information.

Press Release